亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children

血栓性微血管病 伊库利珠单抗 医学 降纤酶 耐火材料(行星科学) 补体系统 内科学 造血干细胞移植 钙调神经磷酸酶 移植 非典型溶血尿毒综合征 胃肠病学 免疫学 抗体 物理 疾病 天体生物学
作者
Michelle Long Schoettler,Seema R. Patel,Elyse Bryson,Laura Deeb,Benjamin Watkins,Muna Qayed,Shanmuganathan Chandrakasan,Taylor Fitch,Katherine Silvis,Jayre A Jones,Satheesh Chonat,Kirsten M. Williams
标识
DOI:10.1016/j.jtct.2023.12.017
摘要

Transplant-associated thrombotic microangiopathy (TA-TMA) is a common and potentially severe complication of hematopoietic cell transplantation. TA-TMA-directed therapy with eculizumab, a complement C5 inhibitor, has resulted in a survival benefit in some studies. However, children with TA-TMA refractory to C5 inhibition with eculizumab (rTA-TMA) have mortality rates exceeding 80%, and there are no other known therapies. Narsoplimab, an inhibitor of the MASP-2 effector enzyme of the lectin pathway, has been studied in adults with TA-TMA as first-line therapy with a response rate of 61%. Although there are limited data on narsoplimab use as a second-line agent in children, we hypothesized, that complement pathways proximal to C5 are activated in rTA-TMA, and that narsoplimab may ameliorate rTA-TMA in children. In this single-center study, children were enrolled on single-patient, Institutional Review Board-approved compassionate use protocols for narsoplimab treatment. Clinical complement lab tests were obtained at the discretion of the treating physician, although all patients were also offered participation in a companion biomarker study. Research blood samples were obtained at the time of TA-TMA diagnosis, prior to eculizumab treatment, at the time of refractory TA-TMA diagnosis prior to the first narsoplimab dose, and 2 weeks after the first narsoplimab dose. Single ELISA kits were used to measure markers of complement activation according to the manufacture's instructions. Five children with rTA-TMA received narsoplimab; 3 were in multiorgan failure and 2 had worsening multiorgan dysfunction at the time of treatment. Additional comorbidities at the time of treatment included sinusoidal obstructive syndrome (SOS; n = 3), viral infection (n = 3), and steroid-refractory stage 4 lower gut grade IV acute graft-versus-host disease (aGVHD, n = 3). Two infants with concurrent SOS and no aGVHD had resolution of organ dysfunction; 1 also developed transfusion-independence (complete response), and the other's hematologic response was not assessable in the setting of leukemia and chemotherapy (partial response). One additional patient achieved transfusion independence but had no improvement in organ manifestations (partial response), and 2 patients treated late in the course of disease had no response. Narsoplimab was well tolerated without any attributed adverse effects. Three patients consented to provide additional research blood samples. One patient with resolution of organ failure demonstrated evidence of proximal pathway activation prior to narsoplimab treatment with subsequent declines in Ba, Bb, C3a, and C5a and increases in C3 in both clinical and research lab tests. Otherwise, there was no clear pattern of other complement markers, including MASP-2 levels, after therapy. In this cohort of ill children with rTA-TMA and multiple comorbidities, 3 patients benefited from narsoplimab. Notably, the 2 patients with resolution of organ involvement did not have steroid-refractory aGVHD, which is thought to be a critical driver of TA-TMA. Additional studies are needed to determine which patients are most likely to benefit from narsoplimab and which markers may be most helpful for monitoring lectin pathway activation and inhibition.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
化羽归尘发布了新的文献求助10
1秒前
mwang完成签到,获得积分10
8秒前
9秒前
李健的小迷弟应助Wakakak采纳,获得10
13秒前
lf发布了新的文献求助10
13秒前
Eunice完成签到,获得积分10
14秒前
19秒前
威武的雨筠完成签到 ,获得积分10
25秒前
研友_VZG7GZ应助哈哈哈哈采纳,获得10
28秒前
momochichu发布了新的文献求助10
29秒前
31秒前
31秒前
35秒前
Wakakak发布了新的文献求助10
36秒前
高贵逍遥完成签到 ,获得积分10
36秒前
wyz完成签到 ,获得积分10
37秒前
39秒前
冰激凌完成签到,获得积分10
40秒前
40秒前
Yu发布了新的文献求助10
42秒前
小乘号子发布了新的文献求助30
42秒前
。。完成签到,获得积分10
43秒前
量子星尘发布了新的文献求助10
45秒前
哈哈哈哈发布了新的文献求助10
46秒前
故意的山河完成签到,获得积分10
48秒前
Linda发布了新的文献求助10
50秒前
struggling2026完成签到 ,获得积分10
55秒前
科研通AI5应助Wakakak采纳,获得10
56秒前
喂喂发布了新的文献求助20
58秒前
lena完成签到 ,获得积分10
1分钟前
情怀应助小乘号子采纳,获得10
1分钟前
1分钟前
深情安青应助深情访文采纳,获得10
1分钟前
星辰大海应助科研通管家采纳,获得10
1分钟前
wanci应助科研通管家采纳,获得10
1分钟前
共享精神应助科研通管家采纳,获得10
1分钟前
大模型应助科研通管家采纳,获得30
1分钟前
1分钟前
半城微凉应助科研通管家采纳,获得10
1分钟前
万能图书馆应助Linda采纳,获得10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976600
求助须知:如何正确求助?哪些是违规求助? 3520700
关于积分的说明 11204482
捐赠科研通 3257320
什么是DOI,文献DOI怎么找? 1798683
邀请新用户注册赠送积分活动 877881
科研通“疑难数据库(出版商)”最低求助积分说明 806613